This compound serves as a key intermediate in the synthesis of dihydropyridine-based calcium channel blockers used in pharmaceutical applications for treating cardiovascular conditions such as hypertension and angina. Its 1,4-dihydropyridine structure, featuring a 2,3-dichlorophenyl group at position 4 and 2,6-dimethyl substituents, along with the bis((butyryloxy)methyl) ester groups at the 3,5-dicarboxylate positions, allows for further derivatization into active drugs or prodrugs. These prodrug forms enhance bioavailability, tissue penetration, and sustained release, while studies focus on targeted delivery to improve specificity and reduce gastrointestinal side effects.